Precision Optics to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). Dr. Joe Forkey, Chief Executive Officer of Precision Optics, will be hosting the presentation and answering questions at the conclusion.
To access the live presentation, please use the following information:
Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub
Date: Wednesday, April 23, 2025Time: 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time)Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NVWebcast: https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/guest_book?session_id=asgk7HdmXJ5TN4druR4pDn
If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor relations team at 1x1@lythampartners.com. 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV
About Precision Optics CorporationFounded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.
About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Company Contact: PRECISION OPTICS CORPORATION22 East BroadwayGardner, Massachusetts 01440-3338Telephone: 978-630-1800
Investor Contact:LYTHAM PARTNERS, LLCRobert BlumTelephone: 602-889-9700poci@lythampartners.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
S&P/TSX composite edges higher in late-morning trading
TORONTO — Canada's main stock index edged higher in late-morning trading as strength in the industrial sector battled weakness in technology and base metal stocks. The S&P/TSX composite index was up 2.03 points at 27,924.88. In New York, the Dow Jones industrial average was up 74.32 points at 44,986.14. The S&P 500 index was down 22.59 points at 6,426.56, while the Nasdaq composite was down 225.40 points at 21,404.37. The Canadian dollar traded for 72.19 cents US compared with 72.42 cents US on Monday. The October crude oil contract was down 64 cents US at US$62.06 per barrel. The December gold contract was down US$11.90 at US$3,366.10 an ounce. This report by The Canadian Press was first published Aug. 19, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Defiance ETFs Launches Leveraged + Income ETFs for Palantir (PLT), Hims & Hers Health (HIMY), and Robinhood Markets (HOOI)
Defiance ETFs Launches Leveraged + Income ETFs for Palantir (PLT), Hims & Hers Health (HIMY), and Robinhood Markets (HOOI) MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leading innovator in thematic and leveraged exchange-traded funds, today announced the launch of three new single-stock leveraged ETFs with income strategies: Defiance Leveraged Long + Income PLTR ETF (NASDAQ: PLT) – providing leveraged exposure to Palantir Technologies. Invest in Gold Thor Metals Group: Best Overall Gold IRA American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Defiance Leveraged Long + Income HIMS ETF (NASDAQ: HIMY) – providing leveraged exposure to Hims & Hers Health. Defiance Leveraged Long + Income HOOD ETF (NASDAQ: HOOI) – providing leveraged exposure to Robinhood Markets. Each ETF combines approximately 150%–200% leveraged exposure to its underlying stock with an options-based credit call spread income strategy, designed to offer investors amplified growth potential and consistent cash flow. What Sets These Funds Apart Leveraged Exposure: Each fund seeks to deliver approximately 150% to 200% of its underlying stock's daily price performance. Income Generation: The options-driven income overlay aims to generate premium income and provide a potential buffer against declines. Accessible Structure: Investors gain targeted, amplified exposure without needing a margin account. Why These Companies? Palantir Technologies: A leader in AI-driven data analytics, providing platforms such as Foundry and Gotham to governments and enterprises worldwide. Hims & Hers Health: A pioneer in personalized telehealth and direct-to-consumer healthcare, redefining access to wellness and treatment. Robinhood Markets: A disruptor in retail investing, expanding access to commission‑free trading and broader financial markets. Investment ObjectivesEach ETF seeks long-term capital appreciation as its primary objective, with a secondary objective of current income. The leveraged strategy provides amplified exposure to the underlying stock, while the income strategy uses credit call spreads to generate premium income and manage risk associated with DefianceFounded in 2018, Defiance is at the forefront of ETF innovation. The firm specializes in thematic, income, and leveraged ETFs, including first-mover leveraged single-stock products that empower investors to take amplified positions in high‑growth companies. IMPORTANT DISCLOSURESThe Funds' investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read carefully before investing. A hard copy of the prospectuses can be requested by calling 833.333.9383. Defiance ETFs LLC is the ETF sponsor. The Funds' investment adviser is Tidal Investments, LLC ('Tidal' or the 'Adviser'). Investing involves risk. Principal loss is possible. An investment in any Fund is not an investment in its underlying company (Palantir Technologies, Hims & Hers Health, or Robinhood Markets). PLT Risks. The Fund invests in swap contracts and options that are based on the share price of Palantir Technologies ('PLTR'). If the share price of PLTR decreases, the Fund will likely lose value and may suffer significant losses. Indirect Investment in PLTR Risk: PLTR is not affiliated with the Trust, the Fund, the Adviser or their affiliates and is not involved with this offering. Investors in the Fund will not have voting rights in PLTR but will be exposed to its performance. PLTR Trading Risk: The trading price of PLTR may be highly volatile and subject to wide fluctuations. PLTR Performance Risk: PLTR may fail to meet publicly announced guidelines or other expectations, which could cause its share price to decline. Software and Data Analytics Industry Risk: Companies in this industry can be significantly affected by competition, technological change, intellectual property disputes, evolving customer demands, and cybersecurity threats. Government Contract Risk: A significant portion of PLTR's revenue is derived from contracts with government agencies that may be modified, delayed, not renewed, or terminated. HIMY Risks. The Fund invests in swap contracts and options that are based on the share price of Hims & Hers Health ('HIMS'). If the share price of HIMS decreases, the Fund will likely lose value and may suffer significant losses. Indirect Investment in HIMS Risk: HIMS is not affiliated with the Trust, the Fund, the Adviser or their affiliates and is not involved with this offering. Investors in the Fund will not have voting rights in HIMS but will be exposed to its performance. HIMS Trading Risk: The trading price of HIMS may be highly volatile and subject to wide fluctuations. HIMS Performance Risk: HIMS may fail to meet publicly announced guidelines or other expectations, which could cause its share price to decline. Telehealth and Consumer Healthcare Industry Risk: Companies in this industry are subject to risks including regulatory changes, evolving healthcare policies, competition, technological disruption, supply chain issues, and changes in consumer preferences. Regulatory and Compliance Risk: HIMS operates in a highly regulated healthcare environment; changes in telehealth regulations, privacy laws, or prescription requirements could materially impact operations and revenue. HOOI Risks. The Fund invests in swap contracts and options that are based on the share price of Robinhood Markets ('HOOD'). If the share price of HOOD decreases, the Fund will likely lose value and may suffer significant losses. Indirect Investment in HOOD Risk: HOOD is not affiliated with the Trust, the Fund, the Adviser or their affiliates and is not involved with this offering. Investors in the Fund will not have voting rights in HOOD but will be exposed to its performance. HOOD Trading Risk: The trading price of HOOD may be highly volatile and subject to wide fluctuations. HOOD Performance Risk: HOOD may fail to meet publicly announced guidelines or other expectations, which could cause its share price to decline. Brokerage and Financial Services Industry Risk: Companies in this industry are subject to extensive regulation, competition, technological change, cybersecurity threats, and market conditions that affect profitability. Changes in interest rates, customer trading volumes, and investor sentiment can directly impact financial performance. Regulatory Risk: Brokerage and trading platform operators are subject to ongoing oversight from multiple regulatory agencies; changes in regulations, enforcement actions, or legal proceedings could adversely impact HOOD's business model and revenues. Additional Risks. Derivatives Risks: Derivative investments can exhibit imperfect correlation to the underlying assets or index and may result in losses greater than the initial investment. Leverage Risk: Swap contracts and options create additional investment exposure to the underlying securities and increase the potential for loss. Compounding and Market Volatility Risk: Over periods longer than a single trading day, compounding may cause performance to differ from the stated leverage target range. High Portfolio Turnover Risk: A high portfolio turnover rate increases transaction costs, which may raise expenses and reduce performance. Non-Diversification Risk: Because the Funds are non-diversified, they may invest a greater percentage of assets in a single issuer or a smaller number of issuers. New Fund Risk: As newly formed funds, they have no operating history, providing limited basis for investors to assess performance or management. Brokerage commissions may be charged on trades. Distributed by Foreside Fund Services, LLC. Contact: David Hanono info@ | 833.333.9383 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
Waldencast PLC (WALD) Q2 2025 Earnings Report Preview: What To Look For
Waldencast PLC (NASDAQ:WALD) is set to release its Q2 2025 earnings on Aug 19, 2025. The consensus estimate for Q2 2025 revenue is $68.11 million, and the earnings are expected to come in at -$0.04 per share. The full year 2025's revenue is expected to be $308.95 million, and the earnings are expected to be -$0.33 per share. More detailed estimate data can be found on the Forecast page. Waldencast PLC (NASDAQ:WALD) Estimate Trends Warning! GuruFocus has detected 3 Warning Signs with WALD. Over the past 90 days, revenue estimates for Waldencast PLC (NASDAQ:WALD) have increased from $308.19 million to $308.95 million for the full year 2025 and from $357.01 million to $357.81 million for 2026. Conversely, earnings estimates have declined from -$0.31 per share to -$0.33 per share for the full year 2025 and remained flat at -$0.26 per share for 2026. Waldencast PLC (NASDAQ:WALD) Reported History In the previous quarter ending on December 31, 2024, Waldencast PLC's (NASDAQ:WALD) actual revenue was $72.10 million, which beat analysts' revenue expectations of $70.65 million by 2.06%. Waldencast PLC's (NASDAQ:WALD) actual earnings were -$0.18 per share, which missed analysts' earnings expectations of -$0.05 per share by -246.15%. After releasing the results, Waldencast PLC (NASDAQ:WALD) was up by 3.61% in one day. Waldencast PLC (NASDAQ:WALD) 12 Month Price Targets Based on the one-year price targets offered by 5 analysts, the average target price for Waldencast PLC (NASDAQ:WALD) is $3.98, with a high estimate of $5.00 and a low estimate of $2.40. The average target implies an upside of 130.06% from the current price of $1.73. Based on GuruFocus estimates, the estimated GF Value for Waldencast PLC (NASDAQ:WALD) in one year is $0, suggesting a downside of -100% from the current price of $1.73. Based on the consensus recommendation from 6 brokerage firms, Waldencast PLC's (NASDAQ:WALD) average brokerage recommendation is currently 2.2, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.
